|View printer-friendly version|
Histogenics Corporation Announces Pricing of Initial Public Offering
The shares described above will be issued pursuant to a written prospectus forming part of the registration statement on Form S-1 filed with and declared effective by the
This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of, these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such state or jurisdiction.
Elissa CoteTel: +1 (781) 547-7900 InvestorRelations@histogenics.com